Epigenomics Gets Septin9 Test Reimbursement in France | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today said that it a French supplementary insurance provider will provide coverage for the firm's Septin9 test for early detection of colorectal cancer.

The Berlin, Germany-based molecular diagnostics firm said that Mutuelle d’Assurance du Corps de Santé Français (MACSF) will reimburse €50 ($68.80) for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: random DNA replication errors play role in cancer, and more.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.